| 5 min read
FDA pilot programs, aging discoveries, and diagnostic advances led the week’s headlines. 
| 4 min read
Neflamapimod shows promise in slowing ALS by targeting protein clumps and restoring nerve cell function.
| 3 min read
A new biological foundation model analyzes genomic patterns across the tree of life and may accelerate disease research and synthetic biology.News
| 4 min read
Wake Forest researchers have reprogrammed macrophages to target metastatic tumors in the brain, offering a potential new approach where conventional therapies struggle.
| 4 min read
Researchers uncover how microbes targeting the colon’s mucus may explain treatment-resistant constipation in Parkinson’s disease and other patients.
| 4 min read
AI and high-throughput functional screening helped researchers design antibodies that selectively activate CB2, reducing inflammation and scar tissue in human liver tissue.
| 3 min read
When science, manufacturing, and regulatory alignment move together, breakthroughs reach patients faster than ever before.
| 4 min read
A first UK birth from a deceased-donor womb transplant, a billion-dollar siRNA deal for GSK, a sobering setback for early cancer blood tests, and more led the news this week.
| 4 min read
High-throughput T-cell receptor sequencing reveals shared immune signatures in celiac disease, opening the door to earlier, less invasive diagnosis and disease monitoring.
| 3 min read
The industry moves from task copilots to integrated discovery systems.
| 4 min read
Generic and biosimilar competition is poised to disrupt billions in annual drug sales, reshaping market dynamics for some of the industry’s most important medicines.
| 4 min read
Emerging clinical trials suggest that the gut microbiome plays a decisive role in how patients respond to immunotherapy.
